Midwest Medical Resources Inc
$1.0K 1 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Sagent Pharmaceuticals
Sagent Pharmaceuticals reported $1,045.20 across General Payments, Research, and Ownership to 59 physicians and teaching hospitals across 59 transactions.
- $1.0K Below-median payer
- All-tracks total
- 59 Below-median volume
- Transactions
- 59 Below-median reach
- Recipients
- +$243.86
- General Payments vs PY2023
Sagent Pharmaceuticals reported $1,045.20 across all CMS Open Payments tracks (General + Research + Ownership) to 59 physicians and teaching hospitals in Program Year 2024 - ranking #1840 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,045.20, averaging $17.72 per recipient.
Sagent Pharmaceuticals's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
10/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer sagent-pharmaceuticals Sagent Pharmaceuticals
$1.0K · #1840/1,925 · 0.0% industry · PY2024
- TOT $1.0K
- RANK #1840
- SHARE 0.0%
- TXN 59
- RCP 59
- CAT 1
- GEN $1.0K
- ΔGEN +$243.86
- TOP1 2.9%
- PY 2024
Volume peers
Nearest volume peer: Midwest Medical Resources Inc ($1.0K)
Sagent Pharmaceuticals sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Sagent Pharmaceuticals's CMS-reported General Payments increased by $243.86 (+30.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SAGENT PHARMACEUTICALSPY2023: SAGENT PHARMACEUTICALSPY2024: Sagent Pharmaceuticals. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $801.34
- PY2024
- $1,045.20
What the Data Shows for Sagent Pharmaceuticals
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Sagent Pharmaceuticals that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
59 transactions worth $1.0K make "Food and Beverage" the top general-payment category in the 1-category breakdown below, 100.0% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 1 types of general payments, Sagent Pharmaceuticals's largest category was "Food and Beverage" at $1.0K - 100.0% of General Payments.
How Sagent Pharmaceuticals divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $1.0K | 59 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $133.75 (12.8%) of $1,045.20 in this company's General Payments records across 59 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Sagent Pharmaceuticals
The five named recipients with the highest reported General Payments from this company
- 1
Ryan Hoover
$30.48 across 1 reported transactions
- 2
Todd Hansen
$26.13 across 1 reported transactions
- 3
David Feece
$26.12 across 1 reported transactions
- 4
Chad Sundquist
$26.12 across 1 reported transactions
- 5
Jermaine Taft
$24.90 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Sagent Pharmaceuticals's spend rank (#1840 of 1,925, bottom 4% by spend) and concentration rank (#1,585 of 1,838, bottom 14% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Conetic Solutions, Inc. : $36.7K total payments, HHI 180
- Pacira Pharmaceuticals Incorporated : $4.8M total payments, HHI 178
- Novo Nordisk AS : $2.4M total payments, HHI 178
- Omeza LLC : $1.5K total payments, HHI 178
- Caldera Medical, Inc : $117.1K total payments, HHI 177
- Karyopharm Therapeutics Inc. : $1.0M total payments, HHI 177
- Sagent Pharmaceuticals (this company) : $1.0K total payments, HHI 177
- Rigel Pharmaceuticals, Inc. : $1.0M total payments, HHI 175
- Servier Pharmaceuticals LLC : $1.5M total payments, HHI 174
- Mirati Therapeutics, Inc. : $322.0K total payments, HHI 171
- Sekisui Diagnostics, LLC : $21.5K total payments, HHI 171
- Baxter Healthcare : $4.8M total payments, HHI 171
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Sagent Pharmaceuticals's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Sagent Pharmaceuticals.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Sagent Pharmaceuticals.
Showing 6 of 1,924 companies with CMS-reported payment data.
Otto Bock HealthCare LP
$1.0K 45 recipients
Compare payment profiles
KaVo Dental Technologies LLC
$990.42 23 recipients
Compare payment profiles
Cosette Pharmaceuticals Inc.
$1.1K 59 recipients
Compare payment profiles
Civica, Inc.
$1.1K 7 recipients
Compare payment profiles
Breg, Inc
$959.96 34 recipients
Compare payment profiles
Put this to use
Sagent Pharmaceuticals ranks #1840 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Sagent Pharmaceuticals. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.